A53T Mutant SNCA Protein Preformed Fibrils (Type 1)
The A53T Mutant SNCA Protein Preformed Fibrils (Type 1) is For Research Use Only
Specificity: ~14.46 kDa
Expression System: E. coli
Buffer: PBS pH 7.4
Storage Temperature: -80ºC
Alternative Names: Active Human Recombinant A53T Mutant Alpha Synuclein Protein Preformed Fibrils (Type 1), A53T mutant alpha synuclein, A53T mutated SNCA, A53T Alpha synuclein PFFs, Ala53thr mutant alpha synuclein, Alpha synuclein pre-formed brils, Alpha synuclein aggregates, Alpha synuclein protein aggregates, Active Alpha synuclein aggregates, Alpha-synuclein protein, Non-A beta component of AD amyloid protein, Non-A4 component of amyloid precursor protein, NACP protein, SNCA protein, NACP protein, PARK1 protein, Alpha synuclein monomers, SYN protein, Parkinson disease familial 1 Protein
Product manufactured in Canada by StressMarq.
Alpha-Synuclein (SNCA) is expressed predominantly in the brain, where it is concentrated in presynaptic nerve terminals. Alpha-synuclein is highly expressed in the mitochondria of the olfactory bulb, hippocampus, striatum and thalamus. Functionally, it has been shown to significantly interact with tubulin, and may serve as a potential microtubule-associated protein. It has also been found to be essential for normal development of the cognitive functions; inactivation may lead to impaired spatial learning and working memory. SNCA fibrillar aggregates represent the major non A-beta component of Alzheimers disease amyloid plaque, and a major component of Lewy body inclusions, and Parkinson’s disease. Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin. The A53T mutation is a missense point mutation where alanine is replaced by threonine at the 53rd amino acid. This mutation has been linked to early-onset Parkinson’s Disease and increased rates of alpha synuclein fibrillization.